Trials / Completed
CompletedNCT00424892
Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
A 6-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Fibromyalgia Syndrome.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
Detailed description
Patients completing study 3151A4-327 have the opportunity to be treated with DVS SR during the 6 month extension study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desvenlafaxine Sustained Release |
Timeline
- Completion
- 2007-06-01
- First posted
- 2007-01-22
- Last updated
- 2007-12-06
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00424892. Inclusion in this directory is not an endorsement.